The Scale Won't Budge: Is Your Weight Loss Plateau Down to the Dose, the Diet — or Both?

You started your weight loss injection — Mounjaro or Wegovy — feeling hopeful. The first few weeks were encouraging. The scale moved. Your appetite changed. Then, somewhere around weeks eight, twelve or sixteen, progress slowed… or stopped altogether.

If this sounds familiar, you are far from alone. The plateau is one of the most common concerns raised by patients on weight loss injections in the UK, and one of the most misunderstood. Before assuming the medication has stopped working or that you simply need a higher dose, it is worth understanding what is actually happening — because the answer is rarely straightforward.

As a GPhC-registered online pharmacy, Happy Pharmacy is committed to providing personal, regulated support throughout your weight loss journey. That means having honest, evidence-based conversations about setbacks, not just successes.

What Is a Weight Loss Plateau — and Is It Normal?

A weight loss plateau occurs when your body weight remains stable for two weeks or more despite continuing your medication and sticking to your usual diet and activity levels. It is important to understand that this is a normal, predictable part of the weight loss process — not a sign of failure.

Clinical trial data consistently show that weight loss on GLP-1 receptor agonists like Wegovy (semaglutide) and dual GIP/GLP-1 agonists like Mounjaro (tirzepatide) tends to follow a recognisable curve: rapid early losses during dose titration, a gradual slowing as the body adapts, and an eventual levelling off at a new biological set point. This pattern was observed across the landmark STEP and SURMOUNT trial series.

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, found that participants on the highest Mounjaro dose (15mg) lost an average of 22.5% of body weight over 72 weeks — but that rate of loss was far from linear throughout the study.

So when your results level off, the first question is not whether the medication has failed. It is whether the plateau is biological, behavioural, or both.

For illustrative purposes. Individual results vary. Data from published clinical trials (refs 1–3).

Could It Be the Dose?

Both Mounjaro and Wegovy use structured dose titration schedules — starting low and increasing gradually to minimise side effects and allow the body to adapt. Mounjaro begins at 2.5mg weekly, working up through 5mg, 7.5mg, 10mg and 12.5mg to a maximum of 15mg. Wegovy starts at 0.25mg, escalating over approximately 16 weeks to the maintenance dose of 2.4mg.

A plateau can sometimes indicate that the current dose is no longer sufficient to maintain the same level of appetite suppression. This may manifest as a gradual return of food cravings, a reduced sense of fullness after meals, or what is sometimes described as the return of 'food noise' — intrusive thoughts about eating that the medication had previously quietened.

If you have been stable at your current dose for some time and weight loss has stalled, speaking with your prescriber about whether a dose increase is clinically appropriate is a sensible next step. Safety is always paramount: NICE guidelines and UK prescribing practice require that dose escalation is reviewed carefully and only undertaken where side effects have settled and the patient is tolerating the current dose well.

It is also worth noting that Wegovy 7.2mg — a higher-dose formulation of semaglutide — has now received approval and is available for patients who have plateaued at the standard 2.4mg dose. A 2025 study of this higher dose found that adults with obesity lost around 21% of their body weight after 72 weeks, suggesting meaningful additional benefit for some individuals.

Could It Be the Diet?

This is where many patients — and some clinicians — underestimate the challenge. Weight loss injections are extraordinarily effective at reducing appetite and improving metabolic signalling, but they are not a replacement for dietary quality. NICE appraisals for semaglutide and for tirzepatide both explicitly state that these medications must be prescribed alongside a reduced-calorie diet and increased physical activity.

The problem is that as the scale stops moving, it is tempting to focus entirely on the medication side of the equation. But several diet-related factors can drive a plateau independently of dose.

Metabolic Adaptation

When you lose weight, your resting metabolic rate decreases. This is a physiological response — your body simply requires fewer calories to function at its new, lower weight. This is sometimes called adaptive thermogenesis, and it means that the dietary approach that worked when you weighed more may no longer create the same calorie deficit at your current weight.

Dietary Drift

Appetite suppression from GLP-1 and GIP/GLP-1 medications can be so effective early on that patients eat very little without much conscious effort. Over time, as the body partially adapts, portion sizes may creep back up subtly — often without the patient realising. This is known as dietary drift, and it is one of the most common contributors to a plateau.

Protein and Muscle Loss

A significant concern in rapid weight loss — particularly on higher-dose medications — is the risk of losing lean muscle mass alongside fat. Muscle is metabolically active tissue, meaning its loss reduces your overall calorie-burning capacity. A 2025 international expert consensus statement published in ScienceDirect, based on a modified Delphi approach with multidisciplinary clinicians, emphasised the importance of adequate protein intake and resistance exercise in patients on GLP-1 based therapies, precisely to protect against this effect.

Ultra-Processed Foods

Even if overall calorie intake appears to have reduced, the quality and composition of your diet matters. A joint nutrition advisory published in the journal Obesity Pillars in 2025 found that minimising ultra-processed, high-glycaemic foods — even on GLP-1 therapy — was associated with better metabolic outcomes and more sustained weight loss. Foods high in refined carbohydrates can drive insulin spikes that work against the medication's mechanism.

Table: Common causes of weight loss plateau on injections and suggested actions.

The Role of Wraparound Support

One of the most important — and frequently overlooked — aspects of effective weight loss injection therapy is the mandatory requirement for wraparound support. NICE does not merely suggest lifestyle support: it mandates it as a condition of prescribing. NHS England guidance confirms that wraparound care — including nutritional and behavioural components — must be available for a minimum of nine months from the point of prescribing.

This requirement exists precisely because medication alone is not a complete solution. When a plateau occurs, it is often the dietary, behavioural, and psychological elements of the programme that need attention — not just the prescription.

At Happy Pharmacy, every patient receives ongoing, personal clinical support as part of their weight loss injection programme. This is not a tick-box exercise: it is a genuine partnership, designed to help patients navigate the challenges that arise throughout their journey — including plateaus.

What the Evidence Says About Getting Back on Track

Research is clear that plateaus are not the end of the road. A 2026 article published by The Conversation, drawing on GLP-1 clinical trial data, confirmed that periods of slower weight loss are a predictable part of the curve, and that adjusting dose, reinforcing lifestyle interventions, and maintaining engagement with a clinical support programme are the most evidence-based responses.

For most patients, the answer is not one single intervention but a combination: a clinical review of current dosing; a dietary audit with qualified input; renewed focus on protein intake and physical activity; and, where appropriate, referral for behavioural support.

The real-world picture is worth acknowledging too. A 2024 meta-analysis of 53 studies covering over 21,000 patients found that, while clinical trial results for tirzepatide averaged around 22% body weight loss, real-world outcomes for GLP-1 therapies tend to sit in the range of 2–8% after one year, with a significant proportion of patients not reaching the 5% threshold.¹⁰ The reasons are multifactorial — and diet, adherence, and support quality are consistently among them.

A Word on Safety

Any changes to dosing must be guided by a qualified prescriber. Self-adjusting your injection dose, sourcing medication from unregulated or unlicensed providers, or switching between treatments without clinical oversight are all risks that can compromise both your safety and your results.

The MHRA regulates all licensed weight loss medications in the UK. Mounjaro and Wegovy are both MHRA-approved treatments with clear prescribing guidelines. Counterfeit and unlicensed versions of these medications continue to circulate online, and their safety profiles are unknown.

Happy Pharmacy operates as a fully regulated, GPhC-registered online pharmacy. Every prescription is issued following a video consultation with a UK-registered prescriber, in line with the GPhC's February 2025 guidance. Your safety is not negotiable — and it is the foundation on which our support is built.

The Bottom Line

A plateau on weight loss injections is not a failure — it is a physiological and behavioural signal that your programme needs attention. The answer is rarely as simple as 'just increase the dose', though dose review may form part of the solution. Diet, metabolic adaptation, muscle preservation, and the quality of your ongoing support all matter enormously.

If you are concerned about your progress on Mounjaro or Wegovy, the best step is to speak to a clinician who understands both the medication and the individual behind it. That is exactly what Happy Pharmacy is here for.

References

1. New England Journal of Medicine. Tirzepatide Once Weekly for the Treatment of Obesity. 

2. New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).

3. New England Joyurnalod Medicine. Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). 

4. NICE Technology Appraisal TA875. Semaglutide for managing overweight and obesity. 2023. nice.org.uk/guidance/ta875

6. NICE Technology Appraisal TA1026. Tirzepatide for managing overweight and obesity. 2024. 

7. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1–based therapies: An expert consensus statement. 

Happy Pharmacy | HappyPharmacy.co.uk | GPhC-Registered Online Pharmacy

This blog is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your treatment.